Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic Gram-negative pathogen. In this study, we uti...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | englanti |
| Julkaistu: |
Elsevier
2025-08-01
|
| Sarja: | Heliyon |
| Aiheet: | |
| Linkit: | http://www.sciencedirect.com/science/article/pii/S2405844025020675 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|